Lactated Ringer vs Normal Saline Solution During Sickle Cell Vaso-Occlusive Episodes

被引:1
|
作者
Alwang, Augusta K. [1 ]
Law, Anica C. [2 ]
Klings, Elizabeth S. [2 ,3 ]
Cohen, Robyn T. [3 ,4 ]
Bosch, Nicholas A. [2 ,5 ]
机构
[1] Boston Univ, Dept Med, Chobanian & Avedisian Sch Med, Boston, MA USA
[2] Boston Univ, Dept Med, Pulm Ctr, Chobanian & Avedisian Sch Med, Boston, MA USA
[3] Boston Univ, Ctr Excellence Sickle Cell Dis, Chobanian & Avedisian Sch Med, Boston, MA USA
[4] Boston Univ, Chobanian & Avedisian Sch Med, Dept Pediat, Pediatic Pulm & Allergy, Boston, MA USA
[5] Boston Univ, Evans Ctr Implementat & Improvement Sci, Chobanian & Avedisian Sch Med, Dept Med, Boston, MA USA
关键词
TARGET TRIAL; SCORE;
D O I
10.1001/jamainternmed.2024.4428
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Importance Sickle cell disease (SCD), a clinically heterogenous genetic hemoglobinopathy, is characterized by painful vaso-occlusive episodes (VOEs) that can require hospitalization. Patients admitted with VOEs are often initially resuscitated with normal saline (NS) to improve concurrent hypovolemia, despite preclinical evidence that NS may promote erythrocyte sickling. The comparative effectiveness of alternative volume-expanding fluids (eg, lactated Ringer [LR]) for resuscitation during VOEs is unclear. Objective To compare the effectiveness of LR to NS fluid resuscitation in patients with SCD and VOEs. Design, Setting, and Participants This multicenter cohort study and target trial emulation included inpatient adults with SCD VOEs who received either LR or NS on hospital day 1. The Premier PINC AI database (2016-2022), a multicenter clinical database including approximately 25% of US hospitalizations was used. The analysis took place between October 6, 2023, and June 20, 2024. Exposure Receipt of LR (intervention) or NS (control) on hospital day 1. Main Outcome and Measures The primary outcome was hospital-free days (HFDs) by day 30. Targeted maximum likelihood estimation was used to calculate marginal effect estimates. Heterogeneity of treatment effect was explored in subgroups. Results A total of 55 574 patient encounters where LR (n = 3495) or NS (n = 52 079) was administered on hospital day 1 were included; the median (IQR) age was 30 (25-37) years. Patients who received LR had more HFDs compared with those who received NS (marginal mean difference, 0.4; 95% CI, 0.1-0.6 days). Patients who received LR also had shorter hospital lengths of stay (marginal mean difference, -0.4; 95% CI, -0.7 to -0.1 days) and lower risk of 30-day readmission (marginal risk difference, -5.8%; 95% CI, -9.8% to -1.8%). Differences in HFDs between LR and NS were heterogenous based on fluid volume received: among patients who received less than 2 L, there was no difference in LR vs NS; among those who received 2 or more L, LR was superior to NS. Conclusion and Relevance This cohort study found that, compared with NS, LR had a small but significant improvement in HFDs and secondary outcomes including 30-day readmission. These results suggest that, among patients with VOEs in whom clinicians plan to give volume resuscitation fluids on hospital admission, LR should be preferred over NS.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Platelet activity in sickle cell vaso-occlusive episodes.
    Chitlur, MB
    Hollon, W
    Buck, S
    Llanto, L
    Thomas, R
    Sarnaik, S
    Warrier, I
    [J]. BLOOD, 2003, 102 (11) : 69B - 70B
  • [2] Intravenous Magnesium Sulfate for Vaso-occlusive Episodes in Sickle Cell Disease
    Goldman, Ran D.
    Mounstephen, William
    Kirby-Allen, Melanie
    Friedman, Jeremy N.
    [J]. PEDIATRICS, 2013, 132 (06) : E1634 - E1641
  • [3] An innovative intervention for the prevention of vaso-occlusive episodes in sickle cell disease
    Jeon, Won Jin
    Joung, Bowon
    Moon, Jin Hyun
    Hino, Christopher
    Park, Daniel
    Pham, Bryan
    Castillo, Dan Ran
    Chong, Esther
    Kaur, Simmer
    Grismore, Chanell
    Cao, Huynh
    [J]. HEMATOLOGY, 2023, 28 (01)
  • [4] Arginine Therapy for Vaso-Occlusive Pain Episodes in Sickle Cell Disease
    Morris, Claudia R.
    Ansari, Michael
    Lavrisha, Lisa
    Sweeters, Nancy
    Kuypers, Frans A.
    Vichinsky, Elliott P.
    [J]. BLOOD, 2009, 114 (22) : 238 - 238
  • [5] Normal saline vs lactated Ringer's solution for ocular irrigation
    McGary, WB
    Ernst, AA
    Nick, TG
    Walker, LA
    [J]. ACADEMIC EMERGENCY MEDICINE, 1998, 5 (04) : 371 - 372
  • [6] Dexmedetomidine as an adjuvant to analgesic strategy during vaso-occlusive episodes in adolescents with sickle cell disease
    Sheehy, K.
    Finkel, J.
    Darbari, D.
    Guerrera, M.
    Quezado, Z.
    [J]. JOURNAL OF PAIN, 2015, 16 (04): : S91 - S91
  • [7] Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease Reply
    Casella, James F.
    Kronsberg, Shari S.
    Gorney, Rebecca T.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (10): : 975 - 976
  • [8] Prasugrel for Sickle Cell Vaso-Occlusive Events
    Badawy, Sherif M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (02): : 185 - 185
  • [9] Dexmedetomidine as an Adjuvant to Analgesic Strategy During Vaso-Occlusive Episodes in Adolescents with Sickle-Cell Disease
    Sheehy, Kathy A.
    Finkel, Julia C.
    Darbari, Deepika S.
    Guerrera, Michael F.
    Quezado, Zenaide M. N.
    [J]. PAIN PRACTICE, 2015, 15 (08) : E90 - E97
  • [10] MARKERS OF SEVERE VASO-OCCLUSIVE PAINFUL EPISODES IN CHILDREN AND ADOLESCENTS WITH SICKLE CELL ANEMIA
    Darbari, Deepika
    Onyekwere, Onyinye
    Campbell, Andrew
    Luchtman-Jones, Lori
    Dham, Niti
    Sable, Craig
    Rana, Sohail
    Ensing, Greg
    Nouraie, Seyed-Mehdi
    Gordeuk, Victor
    Minniti, Caterina
    Castro, Oswaldo
    Kato, Gregory
    [J]. PEDIATRIC BLOOD & CANCER, 2011, 56 (06) : 950 - 950